Famotidine

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-23-D-0006

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Carlsbad, California, UNITED STATES

SourceSAM
Documents2
The Defense Logistics Agency (DLA) Troop Support has issued an award notice for a national contract, identified as SPE2D2-23-D-0006, for the supply of Famotidine. Famotidine is a pharmaceutical product commonly used to treat conditions such as ulcers and gastroesophageal reflux disease, and its procurement falls under the NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing. The associated Product Service Code is 6505, indicating drugs and biologicals. This contract is part of DLA Troop Support’s ongoing efforts to ensure the reliable availability of essential pharmaceuticals for federal use, with the place of performance specified as Carlsbad, California, United States. The contract is linked to the earlier solicitation SPE2D2-22-R-0119, suggesting a competitive process leading to this award. The scope of this procurement encompasses the manufacturing and supply of Famotidine in accordance with federal standards and requirements. The intended outcome is to maintain a consistent and high-quality supply chain for this critical medication, supporting the health and readiness of personnel served by DLA Troop Support. Key requirements for contractors include compliance with all applicable pharmaceutical manufacturing regulations and standards, as outlined in the NAICS 325412 classification. Deliverables are expected to meet stringent quality assurance protocols, ensuring the safety, efficacy, and reliability of the supplied Famotidine. DLA Troop Support, a federal office, serves as the contracting entity for this award. Interested parties or contractors seeking further information or clarification may contact Kristen Baraniewicz ([email protected], 215-737-4484) as the primary point of contact, or Jason Wray ([email protected], 215-737-0614) as the secondary contact. The notice remains active as of January 2, 2024, and is published on SAM.gov, where additional attachments related to the opportunity are available for review. Contractors evaluating this opportunity should note that the contract’s core requirements—pharmaceutical manufacturing expertise, regulatory compliance, and reliable delivery—will remain constant throughout the contract lifecycle. For further details, including access to attachments and official documentation, contractors are encouraged to visit the official notice at: https://sam.gov/opp/c37e39104c7645db84613ba8b48b7095/view.